Anaplastic Large Cell Lymphoma (systemic) · line 2 · Bendamustine monotherapy 90 mg/m² days 1+2 q21d — r/r PTCL incl ALCL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-BENDAMUSTINE-PTCL |
| ID | IND-ALCL-2L-BENDAMUSTINE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-ALCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track broad salvage for r/r ALCL. Practical advantage in UA — accessible off-label via B-cell lymphoma supply pathway. Useful when BV inaccessible or contraindicated by neuropathy.
Used By
Algorithms
ALGO-ALCL-2L- ALGO-ALCL-2L